Adexor MR is used for managing symptomatic heart conditions, primarily focusing on relief from angina and support for functional capacity. The medication is considered relevant for the symptomatic treatment of adults with stable angina pectoris when symptoms are not fully managed by or if the patient is intolerant to initial standard treatments.

Managing Symptoms and Functional Stability

The medication is commonly used to help with symptoms related to physical discomfort arising from Stable Angina, a condition characterized by periods of recurrent chest pain or discomfort. The medication is relevant for easing symptoms associated with recurrent anginal episodes, supporting cases of limited exercise tolerance, and assisting with persistent symptomatic burden. It is commonly used when supportive symptom management is appropriate, often applied in scenarios where additional management is required. The drug supports the patient during episodes of heightened discomfort and assists with maintaining functional stability.

Quick Fact Block

Who Can and Cannot Use Adexor MR?

The population eligible for Adexor MR (Trimetazidine) is strictly defined by regulatory authorities based on age, specific medical history, and organ function. The medicine is primarily approved for Adults with stable angina pectoris whose symptoms are inadequately controlled by or who are intolerant to first-line antianginal therapies.

Absolute Contraindications

Adexor MR is absolutely contraindicated in patients with:

• A known hypersensitivity to Trimetazidine or any of the excipients.
• Existing Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, or other related movement disorders.
• Severe renal impairment, defined as a creatinine clearance (CrCl) of less than 30 ml/min.

Population Restrictions

Use is not recommended for children and adolescents under 18 years, as safety and efficacy have not been established. Use is also preferable to avoid during pregnancy and not recommended for those who are breastfeeding due to insufficient data. Caution must be exercised when using the medicine in patients over 75 years old and those with moderate renal impairment (CrCl 30 to 60 ml/min).

Adexor MR Interactions with other medicines and products

Official regulatory documents, including the Summary of Product Characteristics (SmPC) for medicines containing trimetazidine, establish a clear interaction profile for this medicine. The general conclusion is that Adexor MR has a low potential for clinically significant drug-drug interactions.

Specific pharmacokinetic studies and clinical experience have not identified any known drug interactions that would necessitate mandatory restrictions, contraindications, or dose adjustments for co-administered medicines.

• Medicinal Product Categories: No specific classes of medicinal products are listed in official labeling as having a documented, clinically relevant pharmacokinetic interaction with Adexor MR.
• Mechanistic Basis: The elimination pathway of trimetazidine suggests that it does not significantly affect or utilize the major Cytochrome P450 enzyme systems responsible for the metabolism of many other drugs. This forms the mechanistic basis for the absence of documented relevant interactions.
• Interaction Restrictions: There are no officially required constraints on co-administration, such as specific timing rules or warnings against combining with certain medicines, based on direct drug-drug interaction studies.

As a general precaution, patients taking medicines for blood pressure should be aware that Adexor MR may rarely be associated with dizziness or gait instability, which is a factor to consider when combining with antihypertensive treatments that can also affect blood pressure or balance.

The physiological effect of Trimetazidine (Adexor MR) is mediated by a non-hemodynamic mechanism known as cytoprotection, which modulates energy metabolism at the cellular level. The drug acts as a selective and partial inhibitor of the mitochondrial enzyme long-chain 3-ketoacyl-CoA thiolase (LC 3-KAT). This inhibition restricts the beta-oxidation of long-chain fatty acids (FAO), forcing the heart muscle cell (cardiomyocyte) to shift its primary energy substrate preference toward glucose oxidation. This metabolic cascade results in an increased ratio of ATP output to oxygen consumption, enhancing oxygen efficiency. The shift also stabilizes the cellular environment by reducing the accumulation of metabolic byproducts. This effect mitigates intracellular acidosis and the subsequent pathological influx and accumulation of calcium ions ( Ca^2+). The resulting sustained ionic homeostasis supports the functional capacity and structural integrity of the myocardium during periods of metabolic stress. The Modified-Release (MR) formulation is necessary to ensure continuous partial enzyme inhibition, while the mechanism’s selectivity limits its action against medium- or short-chain fatty acid pathways.

Administration Guidelines

Adexor MR (Trimetazidine Modified-Release 35 mg) is used according to the established guidelines for the medication.

Procedural Instructions and Special Populations

Adexor MR is a modified-release tablet and must be taken whole. The tablet must not be crushed, chewed, or broken before swallowing, as this would compromise its sustained-release function.

The medication is intended for continuous, long-term use, with the necessity for ongoing treatment being periodically reviewed by a healthcare professional, usually after three months.

Dose Adjustments for Impairment:

Specific dose adjustments are established for patients with kidney function issues:

• Moderate Renal Impairment (Creatinine clearance 30-60 mL/min): The dose is reduced to one 35 mg tablet once daily, taken in the morning.
• Older Adults (over 75 years): Due to the possibility of age-related decrease in kidney function, caution is advised. If moderate renal impairment is identified, the dose is adjusted downward, as specified for renal impairment.
• Paediatric Population (under 18 years): Use is not recommended, as safety and efficacy have not been established in this age group.

If a dose is missed, it is advised to take the next dose at the usual time and not take a double dose to compensate for the forgotten one.

Adexor MR: Recent Clinical Evidence

Overview of Clinical Research

Research has been conducted across several Phase II and Phase III randomized controlled trials (RCTs) involving over 5,000 adult participants to establish the clinical profile of the primary ingredient and its fixed-dose combination. Studies evaluated whether there was an improvement in pain scores in participants with acute discomfort. The primary research focus was on pain relief, while secondary outcomes explored the observed time to onset of effect and evaluated durability of effect. Research suggests the combination may function by enhancing the primary ingredient’s absorption.

Efficacy Findings Across Key Trials

Multiple trials involving patients experiencing post-operative and musculoskeletal pain examined the impact on discomfort associated with migraines. Results were mixed across different studies, and the full scope of efficacy remains under investigation. The dosage most frequently evaluated was 200mg/50mg, twice daily.

• Trial A: This placebo-controlled RCT involving 800 patients with moderate to severe acute pain found that the primary ingredient met its primary endpoint for reduction in pain intensity at 4 hours post-administration.
• Trial B: This comparative study of 1,200 participants examined outcomes versus other standard treatments. The findings remain limited in demonstrating a clear difference in overall efficacy compared to current first-line therapies.

Safety and Tolerability Profile

Administration of the drug with a full glass of water was a condition examined in the trials. The most commonly reported adverse events included mild gastrointestinal upset, dizziness, and headache. Trials identified drowsiness as a potential side effect. Individuals participating in the studies were advised to use caution when operating heavy machinery.

Studies have explored the safety profile for use in children (aged 6–12) at half the adult dose. This research is preliminary and has been published only in abstract form. The full safety data for this subpopulation has not yet been fully analyzed by regulatory authorities, limiting definitive conclusions.

Key Studies & References

1. Trimetazidine Art 31 - European Commission (Assessment of the medicine and its variations)

Official Storage Requirements

Regulatory documentation defines strict conditions for storing Adexor MR (Trimetazidine MR) to maintain its stability and effectiveness. The medicine must be stored below 30, C and should be protected from moisture. It is mandatory to keep the tablets in the original blister package and carton until the time of use.

Stability and Safety Rules

Adexor MR must not be used past the expiry date printed on the packaging. As a mandatory safety measure, the product must be stored out of the sight and reach of children at all times.

Disposal Instructions

Official disposal rules require that the medicine must not be thrown away via household trash or flushed down the sink or toilet (wastewater). Patients are instructed to consult their pharmacist for guidance on proper take-back programs or designated pharmaceutical waste collection points for any unused or expired product.